The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.
The company's quarterly revenue of $52.9 million blew away analyst estimates and its net loss of $.47 per share was better than analysts expected.
In the pilot study, Natera's technology detected ubiquitous and heterogeneous tumor mutation variants in early-stage non-small cell lung cancer blood samples.
The complaint alleges that Natera misled shareholders about its business prospects and did not disclose trends that it knew were having a negative impact.
The firm is using Natera's Constellation software platform, which provides cloud-based access to bioinformatics algorithms for clinical genomics applications.
The company's 22q11.2 microdeletion test classified almost 0.5 percent of cases as high risk, among them at least 11 true positives and 50 false positives.
Several new laboratories started to offer NIPT locally in 2015, and some providers have been shifting to less-expensive non-NGS platforms.
Foundation Medicine, Natera, and Genomic Health also showed double-digit percentage increases in December.
In addition to performing Panorama, MedGenome will provide clinical genomic analysis using Natera's Constellation cloud-based software platform.
The company said the draw down is to provide working capital to use on a temporary basis.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.